[Janus kinase inhibitors in immunoinflammatory rheumatic diseases].
Ter Arkh
; 94(5): 605-609, 2022 Jun 17.
Article
in Russian
| MEDLINE | ID: covidwho-2091498
ABSTRACT
Despite great advances in the diagnosis and treatment of immunoinflammatory rheumatic diseases, which have led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology the restoration of the quality of life and the reduction of mortality to the population level are far from being resolved. This served as a stimulus for the study of new approaches to the pharmacotherapy of IVRD, one of which is associated with the use of low molecular weight chemically synthesized drugs that inhibit intracellular "signaling" molecules Janus kinase. Modern advances regarding the use of Janus kinase inhibitors in the treatment of immunoinflammatory rheumatic diseases and COVID -19 are considered.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Rheumatic Diseases
/
Janus Kinase Inhibitors
/
Synthetic Drugs
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
Limits:
Humans
Language:
Russian
Journal:
Ter Arkh
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS